MEI Pharma Inc (MEIP) Can’t Be More Safe. Trades Significantly Higher

September 17, 2017 - By Marry Poplack

The stock of MEI Pharma Inc (NASDAQ:MEIP) is a huge mover today! The stock increased 4.17% or $0.11 on September 15, reaching $2.75. About 241,693 shares traded or 4.96% up from the average. MEI Pharma Inc (NASDAQ:MEIP) has risen 20.90% since September 17, 2016 and is uptrending. It has outperformed by 4.20% the S&P500.
The move comes after 8 months positive chart setup for the $97.52M company. It was reported on Sep, 17 by We have $3.00 PT which if reached, will make NASDAQ:MEIP worth $8.78 million more.

Wall Street await MEI Pharma Inc (NASDAQ:MEIP) to release earnings on November, 14. Analysts forecast earnings per share of $-0.17, down exactly $0.05 or 41.67 % from 2014’s $-0.12 EPS. After posting $-0.12 EPS for the previous quarter, MEI Pharma Inc’s analysts now forecast 41.67 % negative EPS growth.

MEI Pharma Inc (NASDAQ:MEIP) Ratings Coverage

Among 3 analysts covering MEI Pharma (NASDAQ:MEIP), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. MEI Pharma had 7 analyst reports since September 4, 2015 according to SRatingsIntel. Stifel Nicolaus maintained the stock with “Hold” rating in Wednesday, September 6 report. The company was maintained on Wednesday, May 31 by Oppenheimer. As per Monday, June 26, the company rating was maintained by Oppenheimer. The stock has “Buy” rating by Oppenheimer on Wednesday, June 14. The rating was maintained by Oppenheimer with “Buy” on Wednesday, August 2. The firm earned “Hold” rating on Friday, September 4 by Wedbush.

More notable recent MEI Pharma Inc (NASDAQ:MEIP) news were published by: which released: “MEI Pharma-Presage Biosciences on License Deal for Voruciclib” on September 06, 2017, also with their article: “MEI Pharma Reports Second Quarter Fiscal Year 2017 Results” published on February 08, 2017, published: “MEI Pharma Announces Exclusive License Agreement with Presage Biosciences for …” on September 05, 2017. More interesting news about MEI Pharma Inc (NASDAQ:MEIP) were released by: and their article: “MEI Pharma: Double Trouble Or Double Double?” published on July 11, 2017 as well as‘s news article titled: “Helsinn Group and MEI Pharma Announce Upcoming Presentations of Gene Mutation …” with publication date: May 18, 2017.

MEI Pharma, Inc. is an oncology company. The company has market cap of $97.52 million. The Firm is focused on the clinical development of drugs and therapies for treatment of cancer. It has a 41.12 P/E ratio. The Company’s portfolio of clinical drug candidates includes Pracinostat, ME-344 and PWT143.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.